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A major barrier to determine the incidence of influenza disease in the ICU is the difficulty of conducting prospective surveillance studies with laboratory confirmation of influenza virus infection in ICUs. Prospective surveillance for influenza in ICUs would be prohibitively expensive and would require massive sample sizes to make robust incidence estimates. Although several case series of influenza-associated critical illness have been published since the 2009 influenza A (H1N1) pandemic, such studies lack generalizability due to methodological limitations. For example, most of these studies rely on a physician's clinical discretion for influenza testing rather than apply standardized laboratory testing criteria (2) (3) (4) (5) . The U.S. Centers for Disease Control and Prevention (CDC) estimates that 25-60% of all persons hospitalized with an influenza virus infection are either not tested for influenza or have false-negative laboratory tests, often due to use of insensitive influenza tests (6, 7) . In addition, physician recognition of influenza disease is known to be influenced by a patient's clinical presentation and presence of underlying comorbidities (8) . When studies of influenza-associated critical illness do apply standardized laboratory testing criteria, case definitions often require documentation of fever or a radiographic infiltrate for study entry (2, 3, 9, 10) . These criteria will lead to underestimate influenza disease, as they will not capture nonpneumonia processes such as exacerbations of chronic underlying illnesses like congestive heart failure or asthma (11, 12) .
In response to the WHO BrAVe Initiative's call for studies to characterize the burden of critical illness due to influenza virus infection, we estimated the population-attributable risk of influenza-associated critical illness in three western U.S. states.
We hypothesized that influenza contributes to an important proportion of critically ill individuals in the study area.
MATERIALS AND METHODS

Study Design Overview
We briefly summarize the study design here and expand upon the methods in subsequent sections. We conducted a retrospective cohort study from 2003 to 2009 using hospitalization data and influenza surveillance data (13, 14) . We used all inpatient discharge abstracts from community hospitals in the Healthcare Cost and Utilization Project (HCUP) State Inpatient Database (SID) for adults who are 18 years old or older in Arizona, California, and Washington. We obtained influenza surveillance data from CDC. The primary objective was to estimate the proportion of all adult critical illness hospitalizations that are attributable to seasonal influenza. Our exposures of interest were the proportions of specimens that tested positive for influenza viruses. The primary outcome was "critical illness" which we defined by International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis or procedure codes (15) (16) (17) (18) (19) (20) . We linked the hospitalization datasets with the surveillance datasets by calendar time and geographic region. We then used regression models to estimate the frequency of influenza-associated events and compared this statistic to the total number of all-cause critical illness hospitalizations in adults, similar to methods used in other influenza burden of disease studies (21) (22) (23) (24) .
Influenza Virus Surveillance Data CDC conducts influenza virus surveillance in the United States by collecting influenza testing data from participating WHO Collaborating Laboratories and the National Respiratory and Enteric Virus Surveillance System Laboratories (14, 25) . Aggregated data are publicly available by U.S. Federal Region. We used weekly laboratory data from January 2003 to March 2009 for U.S. Federal Regions 9 and 10, which encompass the states in our study area (22) . We collapsed the weekly surveillance data for influenza virus types and subtypes (A/H3N2, A/ H1N1, and B) to create month-level database that we could link to the month-level SID. As differences in the total number of specimen collected over time can bias our model estimates, we standardized the frequency of positive laboratory tests for influenza types and subtypes by dividing the monthly count of positive tests by the number of tests performed during the influenza surveillance year, July-June of the subsequent calendar year. To assess burden of influenza-associated critical illness hospitalizations during periods of influenza circulation, in a secondary analysis, we estimated the number of events in the influenza season, which we defined as the months during which more than 10% of influenza tests performed were positive within a region (26) . We previously showed that influenza virus surveillance data correlate well with data from other U.S. influenza surveillance systems (27) , that most of the laboratory tests from regions 9 and 10 were performed in our three states of interest (20) , and that aggregated region 9 influenza surveillance data are highly correlated with Arizona-specific influenza surveillance data (20) .
Hospitalization Data
The SID contains all inpatient discharge abstracts from community hospitals in participating states, which have been translated into a uniform format to facilitate multistate comparisons and analyses (13) . We used HCUP SID hospitalization data for Arizona, California, and Washington from 2003 through 2009 (8) . The anonymous SID includes numerous data elements for each hospital stay, including primary and secondary diagnoses, primary and secondary procedures, admission and discharge status, patient demographics, and other information. Between 2003 and 2009, the SID for Arizona, California, and Washington contained 98.4% of all community hospitals and data from over 45 noncommunity hospitals (e.g., federal). The primary outcome for this study is "critical illness" which we defined as any hospitalizations with acute respiratory failure (15, 20) , severe sepsis (16) (17) (18) , or in-hospital death (supplemental data, Supplemental Digital Content 1, http://links.lww.com/CCM/B25) (19) . A hospitalization could have had codes for any combination of acute respiratory failure, severe sepsis, and/or in-hospital death, but would have been counted as only one event. Secondary outcomes were each of the critical illness component syndromes. Although these outcomes may not include all critically ill influenza patients, they are common life-threatening conditions that benefit from aggressive delivery of time sensitive care regardless of hospital location.
Statistical Analysis
We adapted negative binomial regression models that were developed by CDC to estimate the incidence of U.S. influenza hospitalizations (21) (22) (23) (24) . We recently piloted this model to estimate the incidence of influenza-associated acute respiratory failure in the same states and time period as this current study (20) . To assess influenza contribution to all critical illness, we aggregated acute respiratory failure events with other critical illness outcomes. Differences in influenza-associated acute respiratory failure incidence estimates from our previous study reflect changes in age groups in the current study.
We fit age-specific negative binomial regression models to monthly events in the three states of interest. We used five age categories: 18-49 years, 50-64 years, 65-74 years, 75-84 years, and 85 years old or older. The model is as follows: where Y i represents the number of outcomes in a particular state during a particular month (t), α is equal to the population size, β 1 through β 4 account for secular trend, β 5 through β 6 account for seasonal trend, and β 9 through β 11 represent standardized proportion of specimens testing positive each month for influenza A (H1N1), influenza A (H3N2), and influenza B in U.S. Federal Regions 9 and 10 in a given month.
We first fit the model to predict our primary outcomethe monthly number of critical illness events. The model accounted for the seasonality of noninfluenza-associated events, some of which may be associated with other respiratory pathogens and some of which are likely due to noninfectious causes. Only a small fraction of events occurring during the winter are thus attributed to influenza infections. As we were interested in the impact of seasonal influenza on critical illness, we did not include data from the 2009 influenza A (H1N1) pandemic. Using the fitted model, we then calculated the number of the influenza-associated outcomes for each influenza type/subtype as the difference between the outcomes estimated from the original data and the outcomes with the given influenza type term set to zero (the difference was set to zero when negative). To calculate the frequency of influenzaassociated events, we combined the estimated monthly outcomes that were attributable to each influenza type/subtype in each state for each age category. This method assumes the influenza virus covariates are nonnegative and independent of each other. Critical illness hospitalizations, either calculated (all-cause events as identified by ICD-9-CM codes) or modeled (influenza-associated events), were numerators in incidence rate calculations. Annual U.S. census state population estimates were used as denominators to calculate populationbased monthly incidence rates of outcomes (28). We then calculated population-attributable risks for influenza-associated events by dividing the modeled incidence estimates by the calculated all-cause event incidence in the same cohort. We calculated 95% CIs for influenza-associated event frequencies, incidences, and population-attributable risks using the nonparametric bootstrap (29) .
We conducted a sensitivity analysis to explore possible confounding by respiratory syncytial virus (RSV). Although RSV is generally considered a virus that causes disease in very young children, there are limited data suggesting that RSV may also contribute to hospitalizations in the elderly (24, 26, (30) (31) (32) , although few studies have identified many adult RSV cases among the critically ill (32) . During the study period, RSV circulated at the same time as influenza except during the 2003-2004 respiratory virus season. In that season, influenza activity began and peaked two months prior to RSV activity. We took advantage of the difference in influenza and RSV circulation to compare influenza-associated events during periods with and without RSV activity. If the incidence rates of influenza-associated critical illness hospitalizations from the primary analysis were similar to those during the period without RSV activity, we would assume that RSV had minimal impact on our modeled estimates.
This study received exempt review status from the Human Subjects Division at the University of Washington. Analyses were performed with SAS (version 9.3; Cary, NC) and R (version 3.0.1; Vienna, Austria) statistical software. 1%) . The overall populationbased incidence for critical illness hospitalizations was 924.2 per 100,000 person-years. Among all adult hospitalizations, 552,224 individuals (1.5%) had acute respiratory failure, 1,440,406 (3.8%) had severe sepsis, and 649,414 (1.7%) were in-hospital deaths. The population-based incidence for each individual syndrome was 247.0 per 100,000 person-years for acute respiratory failure hospitalizations; 644.3 per 100,000 person-years for severe sepsis hospitalizations; and 290.5 per 100,000 person-years for in-hospital death.
Description of Influenza Virus Surveillance
In U.S. Federal Region 9 (Arizona, California, Hawaii, and Nevada) from January 5, 2003, to April 4, 2009, there were 133,043 influenza laboratory tests performed (Fig. 1) . Of these, 14,578 individuals (11.0%) were positive for any influenza virus, 3,889 (2.9%) were positive for influenza A (H1N1), 7,050 (5.3%) were positive for influenza A (H3N2), and 3,639 (2.7%) were positive for influenza B. In U.S. Federal Region 10 (Alaska, Idaho, Oregon, Washington) during the same time period, there were 52,355 influenza tests performed (Fig. 1) . Of these, 6,827 individuals (13.0%) were positive for any influenza virus, 1,453 (2.8%) were positive for influenza A (H1N1), 3,594 (6.9%) were positive for influenza A (H3N2), and 1,780 (3.4%) were positive for influenza B. The influenza season occurred annually between January and March, except in 2003-2004 and 2005-2006 in which the influenza season occurred in the late fall/early winter. There were positive tests for influenza in both regions during every month of the study period.
Influenza-Associated Critical Illness Hospitalizations
Using multivariable regression models, we estimated that there were 26,760 influenza-associated critical illness hospitalizations (95% CI, 14,541, 47,464) in the study area from January 2003 to March 2009 ( Table 1 ). The population-based incidence for influenza-associated critical illness was 12.0 per 100,000 person-years (95% CI, 6.6, 21.6). Compared with the 18-to 49-year age group, the incidence rate ratio for influenza-associated critical illness was greater among persons 50-64 years (10.2), 65-74 years (28.9), 75-84 years (55.2), and 85 years old or older (156.2). Overall, 1.3% of all critical illness hospitalizations (95% CI, 0.7-2.3%) were attributable to influenza, while the population-attributable risk ranged among age groups from 1.0% among persons 18-49 years (95% CI, 0.4-2.2%) to 1.9% among persons 85 years old or older (95% CI, 1.0-3.2%). During the influenza season, influenza-associated events were 3.4% of all critical illness hospitalizations (95% CI, 1.9-5.8%).
We also estimated overall incidence rates for influenza-associated acute respiratory failure hospitalizations (3.6 per 100,000 person-years; 95% CI, 1.8-6.5), severe-sepsis hospitalizations (8.8 per 100,000 person-years; 95% CI, 3.9-16.5), and in-hospital death (3.7 per 100,000 person-years; 95% CI, 2.1-7.1) ( Table 2) . Most influenza-associated critical illness hospitalizations had severe sepsis (73%), whereas a lower proportion had acute respiratory failure (30%) or in-hospital death (31%).
Comparison of Modeled Outcomes to ICD-9-CM-Coded Influenza Hospitalizations
To assess the potential underrecognition of critical illness due to influenza virus infection, we compared the estimated numbers of hospitalizations for each influenza-associated severe illness syndrome with the numbers of hospitalizations coded with influenza diagnoses in the SID databases ( Table 3) . The percentage of the number of influenza-coded hospitalizations divided by the number of modeled influenza-associated hospitalizations was low for critical illness (9.8%), as well as for its component syndromes, acute respiratory failure (13.9%), severe sepsis (9.0%), and in-hospital death (8.1%). The percentage of coded outcomes divided by modeled outcomes was highest in the 18-to 49-year age group for each outcome, and it generally declined with advancing age.
Sensitivity Analysis Assessing Potential Contribution of RSV to Modeled Outcomes
In a sensitivity analysis, we assessed whether we could be misattributing events associated with RSV to influenza. During 2003-2004, when influenza and RSV were not coincident, the estimated influenza-associated critical illness incidence was 10.8 per 100,000 person-years (95% CI, 2.6-29.0), which was similar to annual incidence estimates during subsequent years when influenza and RSV cocirculated. These estimates ranged from 8. We have previously estimated the frequency and incidence of influenza-associated acute respiratory failure using similar methods and the same hospitalization databases (20) , although incidence estimates are slightly different due to the differences in age groups studied.
www.ccmjournal.org
November 2014 • Volume 42 • Number 11
DISCUSSION
Our study suggests that influenza is an important contributor to critical illness. We estimate that influenza-associated events account for 1.3% of all critical illness hospitalizations and 3.4% of critical illness hospitalizations occurring during the influenza season. Assuming similar risks of influenza-associated critical illness in other U.S. states, if we extrapolate our incidence estimates to the 2010 U.S. population and assume no more than one hospitalization per person, we estimate that a mean of about 28,000 adults are hospitalized for influenza-associated critical illness annually (33) . Of these events, approximately 19,000 persons hospitalized with severe sepsis or acute respiratory failure survive to discharge.
The study also suggests that there is a large unrecognized burden of influenza-associated critical illness. Of the total estimated number of hospitalizations with influenza-associated critical illness, only 9.8% had an ICD-9-CM code for influenza disease. Previous research has shown that widespread testing is not common for influenza in pediatric patients at risk for influenza disease and that hospitalized cases with laboratoryconfirmed influenza virus infection often have noninfluenza discharge codes (6, 34, 35) . Other research has shown that 40-63% of hospitalized pediatric seasonal influenza cases may be undetected due to lack of disease recognition, influenzaspecific testing, or false-negative laboratory tests (6, 37, 38) . We found potentially greater underrecognition of influenza in the adult ICU than reported in these studies. Potential reasons for this may be that physicians for adults are less likely to appreciate the effectiveness of influenza treatment (39) , that common case definitions used to identify influenza are insensitive in hospitalized adults (11) , that physicians are using insensitive influenza tests (40) , that many persons with influenza disease progressing to critical illness may no longer have detectable influenza virus (41), or perhaps that a preceding viral prodrome to critical illness is not being sufficiently assessed or acted upon in the critically ill.
Our study should be interpreted in the context of its limitations. Data from Arizona, California, and Washington may not necessarily be generalizable to other U.S. states. Approximately 2 percent of community hospitals in the states in our analysis did not submit data to the SID. Exclusion of discharges from these centers may have slightly lowered our incidence estimates. Our definition of critical illness may classify patients not admitted to an ICU as critically ill. Nevertheless, patients having sepsis with end-organ dysfunction or acute respiratory failure have a high risk of death regardless of whether they are admitted to the ICU, consistent with critical illness. We used a definition of severe sepsis that has been validated against medical record review (17, 42); however, our definition of acute respiratory failure requiring mechanical ventilation may be insensitive (43) . Nevertheless, our incidence rate estimates for severe sepsis and acute respiratory failure are comparable to other studies using different methodologies (15, 16, 44, 45) . Although a recent study has validated our general approach to estimating influenza-associated hospitalizations against prospective surveillance for laboratoryconfirmed influenza in children (18) , our model has not been validated with prospective influenza surveillance among adults or among persons hospitalized for critical illness. We did not have influenza testing data for the critical illness patients in this cohort, and influenza-associated events were modeled but not calculated. Influenza surveillance data are a convenience sample of specimens tested by participating clinical and public health laboratories and may overrepresent ambulatory pediatric patients (46) . However, virologic surveillance data correlate highly with other national influenza surveillance which include adults and persons with severe influenza illness (46) . Our model did not account for the circulation of RSV, although a sensitivity analysis found that estimates of influenza-associated critical illness were similar during periods with and without RSV circulation. The attributable event, incidence rate, and risk calculations assumed that influenza types/subtype correlations are nonnegative and that virus activity is independent by type/subtype. If this assumption is violated, then we may have overestimated the total number of influenza-associated events. Finally, absence of ICD-9-CM coding for influenza disease does not necessarily mean lack of influenza testing, diagnosis, or treatment. Despite these limitations, our study has important implications for practicing clinicians and public health officials. Providers who care for critically ill individuals should have a heightened suspicion for influenza in their patients, and they should have a lower threshold to test those with acute respiratory failure or severe sepsis for influenza, particularly when influenza is known to be circulating in their communities. Public health officials should consider efforts to target critical care providers to increase awareness of influenza and testing of critically ill patients. Mortality among the critically ill is high, and neuraminidase inhibitor therapy has been shown to benefit hospitalized patients with severe influenza disease (47, 48) . WHO and CDC recommend that all persons with acute critical illness receive empiric oseltamivir therapy when influenza is known to be in the patient's community while clinicians await the results of sensitive influenza diagnostic tests (49) (50) (51) . Laboratory testing should not delay treatment and should not rely on insensitive assays, such as rapid influenza diagnostic tests (51) . Additional measures, such as vaccinating medical staff and implementing infection control procedures, are also necessary to protect vulnerable patients from the nosocomial spread of influenza virus (50) .
CONCLUSIONS
Influenza is the most common vaccine-preventable disease in the United States (24, 52) . Our study suggests that influenza is also a common cause of critical illness and that it may be underrecognized by treating physicians. More efforts are needed to improve our ability to determine which critically ill patients should be assessed and treated for influenza disease. Physicians should consider influenza virus infection in patients with critical illness, particularly when influenza is known to be circulating in the community.
